申请人:CENTOGENE AG
公开号:US10420754B2
公开(公告)日:2019-09-24
The present invention is related to a compound of formula (I):
a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof;
for use in a method for the treatment and/or prevention of cancer, wherein
X is selected from the group consisting of N—R1, O and S;
R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl and hydrogen;
R2 is selected from the group consisting of indolyl, substituted indolyl, azaindolyl and substituted azaindolyl; and
R3 is selected from the group consisting of aryl, substituted aryl, unsubstituted heteroaryl, heterocyclyl and substituted heterocyclyl.
本发明涉及一种式(I)化合物:
其药学上可接受的盐、其水合物、其溶液、其代谢物或其原药;
用于治疗和/或预防癌症的方法,其中
X选自由N-R1、O和S组成的组;
R1 选自由烷基、环烷基、芳基、芳烷基和氢组成的组;
R2 选自由吲哚基、取代的吲哚基、偶氮吲哚基和取代的偶氮吲哚基组成的组;和
R3 选自由芳基、取代的芳基、未取代的杂芳基、杂环基和取代的杂环基组成的组。